Multiple system atrophy (MSA) carries a universally poor prognosis, but the natural history of the disease is not well established. A new study prospectively followed a cohort of patients with MSA across multiple centres in the USA. The results provide valuable insight into progression and survival in patients with MSA.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Autoimmune antibody decline in Parkinson’s disease and Multiple System Atrophy; a step towards immunotherapeutic strategies
Molecular Neurodegeneration Open Access 07 June 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wenning, G. K., Colosimo, C., Geser, F. & Poewe, W. Multiple system atrophy. Lancet Neurol. 3, 93–103 (2004).
Low, P. A. et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 14, 710–719 (2015).
Gilman, S. et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670–676 (2008).
Wenning, G. K. et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 12, 264–274 (2013).
Watanabe, H. et al. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 125, 1070–1083 (2002).
Trojanowski, J. Q. et al. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol. Appl. Neurobiol. 33, 615–620 (2007).
Seppi, K. et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 26 (Suppl. 3), S42–S80 (2011).
Fox, S. H. et al. The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson's disease. Mov. Disord. 26 (Suppl. 3), S2–S41 (2011).
Fanciulli, A. & Wenning, G. K. Multiple-system atrophy. N. Engl. J. Med. 372, 249–263 (2015).
Poewe, W., Mahlknecht, P. & Krismer, F. Therapeutic advances in multiple system atrophy and progressive supranuclear palsy. Mov. Disord. http://dx.doi.org/10.1002/mds.26334.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Poewe, W., Krismer, F. Multiple system atrophy—new insight from prospective studies. Nat Rev Neurol 11, 430–431 (2015). https://doi.org/10.1038/nrneurol.2015.124
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2015.124
This article is cited by
-
Autoimmune antibody decline in Parkinson’s disease and Multiple System Atrophy; a step towards immunotherapeutic strategies
Molecular Neurodegeneration (2017)